These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16273604)

  • 1. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.
    Toniutto P; Fabris C; Avellini C; Minisini R; Bitetto D; Rossi E; Smirne C; Pirisi M
    World J Gastroenterol; 2005 Oct; 11(38):5944-50. PubMed ID: 16273604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
    Brandman D; Pingitore A; Lai JC; Roberts JP; Ferrell L; Bass NM; Terrault NA
    Liver Transpl; 2011 Dec; 17(12):1380-6. PubMed ID: 21770018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
    Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
    Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Fornasiere E; Smirne C; Pirisi M
    J Gastroenterol; 2007 Jul; 42(7):543-9. PubMed ID: 17653650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation.
    Baiocchi L; Tisone G; Palmieri G; Rapicetta M; Pisani F; Orlando G; Casciani CU; Angelico M
    Liver Transpl Surg; 1998 Nov; 4(6):441-7. PubMed ID: 9791153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Smirne C; Caldato M; Pirisi M
    Liver Int; 2005 Dec; 25(6):1128-35. PubMed ID: 16343062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression.
    Toniutto P; Minisini R; Fabris C; De Feo T; Marangoni F; Burlone M; Avellini C; Bitetto D; Fornasiere E; Fumolo E; Baccarani U; Pirisi M
    Clin Transplant; 2009; 23(2):184-90. PubMed ID: 19210526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
    Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft.
    Sánchez-Fueyo A; Restrepo JC; Quintó L; Bruguera M; Grande L; Sánchez-Tapias JM; Rodés J; Rimola A
    Transplantation; 2002 Jan; 73(1):56-63. PubMed ID: 11792978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
    Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.
    Wali M; Harrison RF; Gow PJ; Mutimer D
    Gut; 2002 Aug; 51(2):248-52. PubMed ID: 12117889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation.
    Hanouneh IA; Feldstein AE; McCullough AJ; Miller C; Aucejo F; Yerian L; Lopez R; Zein NN
    Liver Transpl; 2008 Sep; 14(9):1287-93. PubMed ID: 18756451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P; Loreno M; Russo FP; Germani G; Galligioni A; Senzolo M; Cillo U; Zanus G; Fagiuoli S; Rugge M
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.
    Subramanian V; Seetharam AB; Vachharajani N; Tiriveedhi V; Angaswamy N; Ramachandran S; Crippin JS; Shenoy S; Chapman WC; Mohanakumar T; Anderson CD
    Transplantation; 2011 Dec; 92(11):1259-68. PubMed ID: 22011763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
    Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors in liver retransplantation: a single-center experience.
    Crivellin C; De Martin E; Germani G; Gambato M; Senzolo M; Russo FP; Vitale A; Zanus G; Cillo U; Burra P
    Transplant Proc; 2011 May; 43(4):1110-3. PubMed ID: 21620065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity.
    Pelletier SJ; Iezzoni JC; Crabtree TD; Hahn YS; Sawyer RG; Pruett TL
    Liver Transpl; 2000 Jan; 6(1):44-53. PubMed ID: 10648577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.